Myriad Genetics Inc (MYGN) · Oct 9, 2026 · Exec change
$1.32M severance — $1,322,294 lump-sum payment plus accelerated time-based equity
Myriad Genetics formalizes former commercial chief Brian Donnelly’s separation, including $1.32 million severance and accelerated equity vesting.
Myriad is trying to improve commercial execution around its cancer-care continuum and newer molecular-diagnostic products while responding to weaker 2026 business trends and a lower revenue outlook. This filing mostly closes out an already-known leadership change. Brian Donnelly’s departure as chief commercial officer was disclosed on September 16, 2026, and Vishal Sikri had already been appointed to lead the commercial organization, so the strategic signal is not new. The new information is the economic settlement: “Mr. Donnelly will receive a lump sum severance payment of $1,322,294.” 〔0〕
| Item | Filing detail |
|---|---|
| Lump-sum severance | $1,322,294 (Separation Agreement) |
| Separation date | September 21, 2026 (Separation Agreement) |
| Agreement effective date | October 14, 2026, if not revoked (Separation Agreement) |
| Equity treatment | Time-based awards scheduled to vest within two years are accelerated or monthly-vested over that period (Separation Agreement) |
The cost is meaningful but not strategically transformative. In addition to the cash payment, the agreement accelerates certain time-based equity awards and preserves potential performance-based awards for up to two years. “The vesting of all outstanding time-based equity awards previously granted to Mr. Donnelly that were scheduled to vest on or before the date two years following the Separation Date will be accelerated.” The filing does not disclose the value of those equity awards, so the total separation cost cannot be quantified from this document alone.
Bottom line: This is a routine financial cleanup of a leadership departure that was already public, not a fresh change to Myriad’s commercial strategy. It adds a disclosed cash and equity cost, but barely changes the broader business story.**
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!